INDV Stock Analysis: Indivior Ordinary Shares | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 4.282m USD | 12M Return: 10.9% | US45579U1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 77.8M
EPS Trend: 78.8%
Qual. Beats: 7
Rev. Trend: 93.3%
Qual. Beats: 8
Warnings
Tailwinds
Seasonality 11.8 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Indivior Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing, manufacturing, and commercializing buprenorphine-based prescription medicines for the treatment of opioid use disorder (OUD) and related conditions, operating primarily in the United States, Europe, Canada, Australia, and select international markets. Its commercial portfolio is anchored by SUBLOCADE, a once-monthly extended-release buprenorphine injection, and SUBOXONE Film, a buprenorphine/naloxone sublingual film, with additional legacy products including SUBOXONE Tablet and SUBUTEX Tablet. The company was incorporated in 2014, is headquartered in North Chesterfield, Virginia, and previously operated under the name Indivior PLC before adopting its current corporate name in January 2026.
Within the broader Health Care sector, Indivior sits in the Biotechnology sub-industry, where it occupies a leading position in medication-assisted treatment (MAT) for OUD, a therapeutic area shaped by the ongoing opioid crisis in the U.S. and other developed markets. Its growth strategy centers on shifting patient share from generic sublingual formulations toward its branded long-acting injectable SUBLOCADE, while advancing a focused pipeline that includes INDV-2000, a selective orexin-1 receptor antagonist in Phase 2 development, and INDV-6001, a long-acting injectable buprenorphine candidate being co-developed with Alar Pharmaceuticals.
- SUBLOCADE injection sales accelerate on strong U.S. demand
- SUBOXONE Film revenue erodes from ongoing generic competition
- INDV-2000 Phase 2 opioid use disorder trial readout approaches
| Net Income: 450.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -6.85 > 1.0 |
| NWC/Revenue: -36.46% < 20% (prev -3.64%; Δ -32.82% < -1%) |
| CFO/TA 0.07 > 3% & CFO 96.0m > Net Income 450.0m |
| Net Debt (209.0m) to EBITDA (568.0m): 0.37 < 3 |
| Current Ratio: 0.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (122.0m) vs 12m ago -5.43% < -2% |
| Gross Margin: 85.15% > 18% (prev 84.67%; Δ 0.48% > 0.5%) |
| Asset Turnover: 100.00% > 50% (prev 83.40%; Δ 16.60% > 0%) |
| Interest Coverage Ratio: 32.65 > 6 (EBIT TTM 555.0m / Interest Expense TTM 17.0m) |
| A: -0.38 (Total Current Assets 800.0m - Total Current Liabilities 1.30b) / Total Assets 1.33b |
| B: -0.15 (Retained Earnings -197.0m / Total Assets 1.33b) |
| C: 0.40 (EBIT TTM 555.0m / Avg Total Assets 1.37b) |
| D: -0.04 (Book Value of Equity -60.0m / Total Liabilities 1.39b) |
| Altman-Z'' = -0.28 = B |
| DSRI: 0.90 (Receivables 286.0m/272.0m, Revenue 1.37b/1.18b) |
| GMI: 0.99 (GM 84.67% / 85.15%) |
| AQI: 1.08 (AQ_t 0.26 / AQ_t-1 0.24) |
| SGI: 1.16 (Revenue 1.37b / 1.18b) |
| TATA: 0.27 (NI 450.0m - CFO 96.0m) / TA 1.33b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of November 12, 2026, the stock is trading at USD 26.74 with a total of 6,076,286 shares traded. Over the past week, the price has changed by -2.23%, over one month by -4.43%, over three months by -10.32% and over the past year by +10.92%.
Current recommended Stop Loss: 24.70 (which is 7.6% or 1.1 ATR below the current price).
Indivior Ordinary Shares has no consensus analysts rating.
| Analysts Target Price | 49.5 | 85.1% |
P/E Trailing = 10.1625
P/E Forward = 9.3985
P/S = 3.1167
P/B = 145.2492
Revenue TTM = 1.37b USD
EBIT TTM = 555.0m USD
EBITDA TTM = 568.0m USD
Long Term Debt = 290.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 495.0m USD (from shortTermDebt, last quarter)
Debt = 514.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.0m
Net Debt = 209.0m USD (calculated: Debt 514.0m - CCE 305.0m)
Enterprise Value = 4.49b USD (4.28b + Debt 514.0m - CCE 305.0m)
Interest Coverage Ratio = 32.65 (Ebit TTM 555.0m / Interest Expense TTM 17.0m)
EV/FCF = 144.9x (Enterprise Value 4.49b / FCF TTM 31.0m)
FCF Yield = 0.69% (FCF TTM 31.0m / Enterprise Value 4.49b)
FCF Margin = 2.26% (FCF TTM 31.0m / Revenue TTM 1.37b)
Net Margin = 32.75% (Net Income TTM 450.0m / Revenue TTM 1.37b)
Gross Margin = 85.15% ((Revenue TTM 1.37b - Cost of Revenue TTM 204.0m) / Revenue TTM)
Gross Margin QoQ = 85.67% (prev 85.71%)
Tobins Q-Ratio = 3.37 (Enterprise Value 4.49b / Total Assets 1.33b)
Interest Expense / Debt = 3.31% (Interest Expense 17.0m / Debt 514.0m)
Taxrate = 16.36% (88.0m / 538.0m)
NOPAT = 464.2m (EBIT 555.0m * (1 - 16.36%))
Current Ratio = 0.61 (Total Current Assets 800.0m / Total Current Liabilities 1.30b)
Debt / Equity = -8.57 (negative equity) (Debt 514.0m / totalStockholderEquity, last quarter -60.0m)
Debt / EBITDA = 0.37 (Net Debt 209.0m / EBITDA 568.0m)
Debt / FCF = 6.74 (Net Debt 209.0m / FCF TTM 31.0m)
Total Stockholder Equity = -127.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 32.75% (Net Income 450.0m / Total Assets 1.33b)
RoE = -352.9% (negative equity) (Net Income TTM 450.0m / Total Stockholder Equity -127.5m)
RoCE = 341.5% (EBIT 555.0m / Capital Employed (Equity -127.5m + L.T.Debt 290.0m))
RoIC = 101.5% (NOPAT 464.2m / Invested Capital 457.3m)
WACC = 7.08% (E(4.28b)/V(4.80b) * Re(7.60%) + D(514.0m)/V(4.80b) * Rd(3.31%) * (1-Tc(0.16)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -57.70 | Cagr: -4.35%
[DCF] Terminal Value 73.10% ; FCFF base≈70.6m ; Y1≈61.9m ; Y5≈50.0m
[DCF] Fair Price = 5.03 (EV 802.9m - Net Debt 209.0m = Equity 593.9m / Shares 118.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 78.82 | EPS CAGR: 48.55% | SUE: 2.04 | # QB: 7
Revenue Correlation: 93.29 | Revenue CAGR: 7.38% | SUE: 1.47 | # QB: 8
EPS current Quarter (2027-03-31): EPS=0.94 | Chg30d=-12.73% | Revisions=+40% | Analysts=2
EPS current Year (2026-12-31): EPS=4.42 | Chg30d=+0.14% | Revisions=+50% | GrowthEPS=+76.6% | GrowthRev=+7.5%
EPS next Year (2027-12-31): EPS=4.51 | Chg30d=-7.71% | Revisions=+50% | GrowthEPS=+2.1% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +73% (up=8, down=0)